- Home
- FEBO vs SNTI Comparison
FEBO vs SNTI Comparison
Compare FEBO & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- SNTI
- Stock Information
- Founded
- FEBO 1993
- SNTI 2016
- Country
- FEBO Hong Kong
- SNTI United States
- Employees
- FEBO N/A
- SNTI N/A
- Industry
- FEBO
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- FEBO
- SNTI Health Care
- Exchange
- FEBO Nasdaq
- SNTI Nasdaq
- Market Cap
- FEBO 14.0M
- SNTI 21.3M
- IPO Year
- FEBO 2023
- SNTI N/A
- Fundamental
- Price
- FEBO $1.27
- SNTI $3.96
- Analyst Decision
- FEBO
- SNTI Strong Buy
- Analyst Count
- FEBO 0
- SNTI 1
- Target Price
- FEBO N/A
- SNTI $12.00
- AVG Volume (30 Days)
- FEBO 8.4K
- SNTI 30.3K
- Earning Date
- FEBO 10-03-2024
- SNTI 03-20-2025
- Dividend Yield
- FEBO N/A
- SNTI N/A
- EPS Growth
- FEBO N/A
- SNTI N/A
- EPS
- FEBO N/A
- SNTI N/A
- Revenue
- FEBO $16,319,897.00
- SNTI N/A
- Revenue This Year
- FEBO N/A
- SNTI $11.52
- Revenue Next Year
- FEBO N/A
- SNTI $78.57
- P/E Ratio
- FEBO N/A
- SNTI N/A
- Revenue Growth
- FEBO 9.01
- SNTI N/A
- 52 Week Low
- FEBO $1.20
- SNTI $1.52
- 52 Week High
- FEBO $17.68
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- FEBO 38.48
- SNTI 45.36
- Support Level
- FEBO $1.20
- SNTI $3.92
- Resistance Level
- FEBO $1.39
- SNTI $4.50
- Average True Range (ATR)
- FEBO 0.09
- SNTI 0.26
- MACD
- FEBO 0.01
- SNTI -0.03
- Stochastic Oscillator
- FEBO 24.22
- SNTI 20.59
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.